161 related articles for article (PubMed ID: 1783360)
21. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 2nd communication: studies in dogs.
Ohhara H; Ogawa T; Takeda M; Katoh H; Daiku Y; Igarashi T
Arzneimittelforschung; 1989 Jan; 39(1):38-45. PubMed ID: 2719742
[TBL] [Abstract][Full Text] [Related]
22. Increases in inotropic state without change in heart rate: combined use of dobutamine and zatebradine in conscious dogs.
Hettrick DA; Pagel PS; Lowe D; Tessmer JP; Warltier DC
Eur J Pharmacol; 1996 Dec; 316(2-3):237-44. PubMed ID: 8982692
[TBL] [Abstract][Full Text] [Related]
23. Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure.
Sonnenblick EH; Grose R; Strain J; Zelcer AA; LeJemtel TH
Circulation; 1986 Mar; 73(3 Pt 2):III162-7. PubMed ID: 3510772
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology of the bipyridines: amrinone and milrinone.
Alousi AA; Johnson DC
Circulation; 1986 Mar; 73(3 Pt 2):III10-24. PubMed ID: 2417744
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of milrinone on the electrocardiogram and the cardiac hemodynamics of rats with pressure overload-induced congestive heart failure.
Desjardins S; Cauchy MJ
Arch Int Pharmacodyn Ther; 1989; 301():182-99. PubMed ID: 2624514
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular pharmacology of the vasodilator-cardiotonic agent, 349U85.
Steffen RP; Wastila WB
J Cardiovasc Pharmacol; 1992 Oct; 20(4):579-89. PubMed ID: 1280714
[TBL] [Abstract][Full Text] [Related]
27. Positive inotropic and vasodilating effects of amrinone and milrinone in isolated canine heart.
Sys SU; Boels PJ; Brutsaert DL
J Cardiovasc Pharmacol; 1987 Oct; 10(4):445-9. PubMed ID: 2444798
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency.
Pagel PS; Hettrick DA; Warltier DC
Basic Res Cardiol; 1996; 91(4):296-307. PubMed ID: 8874779
[TBL] [Abstract][Full Text] [Related]
29. A sodium channel enhancer, LY341311, increases myocardial contractile performance without increasing heart rate in conscious normal dogs: a comparison with dobutamine.
Gill RM; Jones BD; Steinberg MI; Shen W
J Card Fail; 2002 Feb; 8(1):33-42. PubMed ID: 11862581
[TBL] [Abstract][Full Text] [Related]
30. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs.
Schwarte LA; Picker O; Bornstein SR; Fournell A; Scheeren TW
Crit Care Med; 2005 Jan; 33(1):135-42; discussion 246-7. PubMed ID: 15644660
[TBL] [Abstract][Full Text] [Related]
31. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents.
Tisdale JE; Patel R; Webb CR; Borzak S; Zarowitz BJ
Prog Cardiovasc Dis; 1995; 38(2):167-80. PubMed ID: 7568905
[TBL] [Abstract][Full Text] [Related]
32. Myocardial and vascular actions of milrinone.
Colucci WS
Eur Heart J; 1989 Aug; 10 Suppl C():32-8. PubMed ID: 2680495
[TBL] [Abstract][Full Text] [Related]
33. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
Travill CM; Pugh S; Noble MI
Clin Ther; 1994; 16(5):783-92. PubMed ID: 7859237
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Karlsberg RP; DeWood MA; DeMaria AN; Berk MR; Lasher KP
Clin Cardiol; 1996 Jan; 19(1):21-30. PubMed ID: 8903534
[TBL] [Abstract][Full Text] [Related]
35. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
Meissner A; Schmelzle T; Simon R
Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
[TBL] [Abstract][Full Text] [Related]
37. Ouabain-induced coronary vasoconstriction in cats is not neurally mediated.
Nair BA; Murad YZ; Brody MJ; Gutterman DD
Clin Exp Pharmacol Physiol; 2001 Jul; 28(7):510-7. PubMed ID: 11422216
[TBL] [Abstract][Full Text] [Related]
38. [Additive effects of milrinone and dobutamine in severe heart failure].
Meissner A; Herrmann G; Gerdesmeyer L; Simon R
Z Kardiol; 1992 May; 81(5):266-71. PubMed ID: 1621407
[TBL] [Abstract][Full Text] [Related]
39. Acute effects of intravenous milrinone in heart failure.
Rettig GF; Schieffer HJ
Eur Heart J; 1989 Aug; 10 Suppl C():39-43. PubMed ID: 2680496
[TBL] [Abstract][Full Text] [Related]
40. The effects of dobutamine, propranolol and nitroglycerin on an experimental canine model of congestive heart failure.
Kamijo T; Tomaru T; Miwa AY; Nakamura F; Kido H; Sugimoto T; Uchida Y
Jpn J Pharmacol; 1994 Jul; 65(3):223-31. PubMed ID: 7799523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
